Zoetis (NYSE:ZTS – Get Free Report) updated its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 6.150-6.250 for the period, compared to the consensus earnings per share estimate of 6.870. The company issued revenue guidance of $9.1 billion-$9.3 billion, compared to the consensus revenue estimate of $9.8 billion.
Zoetis Trading Down 6.1%
Shares of ZTS stock opened at $72.53 on Friday. The stock has a market cap of $30.41 billion, a price-to-earnings ratio of 11.95, a PEG ratio of 1.34 and a beta of 0.74. The stock has a 50-day moving average of $76.66 and a 200-day moving average of $100.75. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80. Zoetis has a 1-year low of $71.47 and a 1-year high of $160.48.
Zoetis (NYSE:ZTS – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 70.95%. The firm had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. During the same quarter last year, the business earned $1.76 EPS. The company’s revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, equities research analysts forecast that Zoetis will post 6.2 earnings per share for the current year.
Zoetis Dividend Announcement
Analyst Ratings Changes
Several research analysts recently issued reports on ZTS shares. Weiss Ratings cut Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 12th. Morgan Stanley set a $85.00 price objective on Zoetis in a research note on Friday. UBS Group cut their price objective on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a report on Friday. TD Cowen reduced their target price on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a research note on Tuesday, June 30th. Finally, William Blair reiterated a “market perform” rating on shares of Zoetis in a report on Thursday. Seven analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Zoetis has an average rating of “Hold” and an average target price of $115.50.
Read Our Latest Analysis on Zoetis
Insider Buying and Selling at Zoetis
In related news, Director Paul Bisaro purchased 2,000 shares of the business’s stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the acquisition, the director directly owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Frank A. Damelio bought 6,650 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The shares were purchased at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the acquisition, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. This trade represents a 44.91% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 11,650 shares of company stock valued at $886,384 over the last three months. 0.22% of the stock is currently owned by insiders.
Trending Headlines about Zoetis
Here are the key news stories impacting Zoetis this week:
- Positive Sentiment: Zoetis reported second-quarter adjusted earnings of $1.87 per share, above the $1.84–$1.85 analyst consensus and up from $1.76 a year earlier. The earnings beat provides some support for the stock. Zoetis Surpasses Q2 Earnings Estimates
- Positive Sentiment: JPMorgan lowered its price target from $130 to $115 but maintained an Overweight rating, implying substantial potential upside from recent levels. The target reduction reflects more conservative estimates rather than a bearish long-term view.
- Neutral Sentiment: Zoetis appointed James “Jay” Saccaro as executive vice president and chief financial officer, with the announcement also describing an expanded finance and operating leadership role. The change may improve execution, but its near-term effect on results is unclear. Zoetis Appoints Jay Saccaro
- Negative Sentiment: Second-quarter revenue was $2.47 billion, below the $2.50 billion consensus and essentially flat year over year. Management cited weaker veterinary traffic, customer price sensitivity and competitive pressure in companion-animal products, with promotions being used to defend market share. ZTS Q2 Earnings Call Flags Deeper Companion Animal Pressure
- Negative Sentiment: Zoetis cut fiscal 2026 guidance to adjusted EPS of $6.15–$6.25 from expectations near $6.87, and revenue guidance to $9.1–$9.3 billion versus consensus of roughly $9.8 billion. The outlook reduction is the primary reason the stock has declined despite the quarterly earnings beat. Zoetis Q2 Earnings Beat Estimates, Revenues Miss, 2026 View Cut
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of ZTS. Pinnacle Financial Partners Inc. lifted its stake in shares of Zoetis by 34.6% in the 3rd quarter. Pinnacle Financial Partners Inc. now owns 62,531 shares of the company’s stock valued at $9,150,000 after acquiring an additional 16,080 shares during the last quarter. Brighton Jones LLC lifted its position in shares of Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after purchasing an additional 2,978 shares during the period. Colter Lewis Investment Partners LLC bought a new stake in shares of Zoetis during the 4th quarter valued at about $205,000. Opal Capital LLC purchased a new position in shares of Zoetis during the fourth quarter valued at about $215,000. Finally, OpenArc Corporate Advisory LLC bought a new position in Zoetis in the fourth quarter worth about $202,000. 92.80% of the stock is currently owned by institutional investors.
Zoetis Company Profile
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Featured Stories
- Five stocks we like better than Zoetis
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
- Why These 3 Equal Weight ETFs Have Outperformed the S&P This Year
- MarketBeat Week in Review – 08/03 – 08/07
- Datadog’s Drop Says More About Expectations Than Earnings
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
